HIMS · Hims & Hers Health, Inc.Hims & Hers Health, Inc.

Partnership with $NVO and dropped lawsuit provide revenue stream expansion and regulatory clarity, eliminating major legal risk.

HIMS' moat is network capture of retail audiences, enabling latent monetization streams similar to HOOD's cross-selling. Regulatory clarity from last Friday removes key risks, and the upside is clear if new monetization avenues are executed.

HIMS value is derived from its distribution network, not the drugs sold, similar to Amazon's delivery network.

HIMS has built a global retail healthcare distribution monopoly through acquisitions, and with regulatory clarity, has significant monetization potential.

HIMS stickiness is due to difficulty switching medical providers, not network effects, making it a moat.

HIMS is bullish due to its global distribution network built through M&A, with parallels to META's acquisition spree and HOOD's cross-selling capabilities.

HIMS has built a massive global healthcare retail network through strategic acquisitions (Zava, Livewell, Eucalyptus) without regulatory pushback, reminiscent of META's platform acquisitions and HOOD's cross-selling potential. Monetization of this distribution network is the key upside driver.

HIMS has built the largest independent global retail DTC distribution network through acquisitions, and with regulatory headwinds cleared (NVO partnership, FDA dropping threats), it can cross-sell products similar to HOOD, leading to significant revenue monetization.

Valuing $HIMS based on distribution network and retail capture angle, not individual pill sales.

HIMS's main valuation is derived from its unique global retail DTC distribution network built via recent acquisitions, unlocking latent revenue streams similar to how HOOD scaled in financial industry.

HIMS has untapped revenue potential from its global DTC retail distribution moat, similar to META's early acquisitions and HOOD's cross-selling. After acquiring three major competitors without regulatory friction and with shorts trapped due to the NVO partnership and lawsuit termination, risk/reward favors going long.

Recent acquisitions give HIMS the global retail market for DTC healthcare, with latent cross-selling opportunities that are hard to model, making short selling extremely risky.

HIMS stock is up 64% with record short interest of 41.6%, creating potential for a violent squeeze if buying pressure and improving fundamentals continue. The company has strong tailwinds from global acquisitions (META-like), cross-selling opportunities (HOOD-like), and a surprise partnership with NVO. Personal conviction is high.

Andrew Huberman, a prominent figure in health, spotlighted $HIMS and said it was set to 'soar', implying a bullish outlook. The post also notes high short interest (41% of float), suggesting potential for a squeeze.

Combining HIMS' DTC distribution network with TEM's personalized sequencing and AI treatment into a scalable product could revolutionize personalized AI medicine, targeting the entire human population as TAM.

List of 30 US stocks with brief bullish theses covering semis, AI, space, rare earths, etc.

Announcement is bullish catalyst for HIMS revenue re-acceleration, leveraging peptide market, DTC distribution, and high margins.

HIMS is down 44% despite multiple positive developments including NVO de-risking, global acquisitions, peptide arc endorsement, friendlier macro, and high short interest creating inherent buying pressure.

Expects HIMS to recover to at least $40 over time, building on prior de-risking and growth catalysts.

Bullish on TTD, HIMS, and RDDT with specific price targets: TTD 40-50% upside to low 30s, HIMS mean reversion to $40, RDDT recovery to $200+ in better macro.